Rogers Corporation (ROG)
NYSE: ROGIndustrialsMajor ChemicalsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ROG stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.95B
- P/E (TTM)
- 43.83
- Forward P/E
- 23.30
- EPS (TTM)
- $2.50
- Dividend yield
- None
- Ex-dividend date
- Jan 9, 1992
- 52-week range
- 78.82 – 169.00
- Day range
- 109.00 – 119.65
- Volume / Avg
- 347.03K / 239.56K
- Beta
- —
- Shares outstanding
- 17.80M
52-week range
ROG stock today
On Nov 20, ROG ended the session at $109.57, shedding $10.87 (9.03%), versus the S&P 500's 3.70% decline. At this level, ROG sits in the middle of its 52-week range of $78.82 to $169.00: 35.2% below the high, set on Jun 22, 2026 and 39.0% above the low. ROG is up 19.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 36.8%.
At 43.8x trailing earnings, Rogers trades above the peer-group median of 26.4x. Its forward P/E of 23.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Rogers
Company profileRogers Corporation designs, develops, manufactures, and sells engineered materials and components in the United States, other Americas, China, other Asia Pacific countries, Germany, Europe, the Middle East, and Africa. It operates in two Advanced Electronics Solutions (AES), Elastomeric Material Solutions (EMS) segments. The AES segment offers circuit materials, ceramic substrate materials, busbars, and cooling solutions for applications in electric and hybrid electric vehicles, automotive, aerospace and defense, renewable energy, wireless infrastructure, mass transit, industrial, connected devices, and wired infrastructure markets.
- Sector
- Industrials
- Industry
- Major Chemicals
- CEO
- Mr. Ali El-Haj
- Headquarters
- Chandler, AZ
- Employees
- 3,000
- IPO year
- 1960
- Website
- rogerscorp.com
Financial highlights
Full financialsIn fiscal 2025, Rogers generated $810.8 million in revenue, down 2.3% from fiscal 2024, its first annual decline since 2024. Rogers reported a net loss of $61.8 million, compared with net income of $26.1 million a year earlier. Gross margin was 31.7% (down from 33.4%) and operating margin -5.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $810.80M | $830.10M | $908.40M | $971.20M | $932.90M |
| Growth | -2.33% | -8.62% | -6.47% | +4.11% | +16.24% |
| Net income | $-61.80M | $26.10M | $56.60M | $116.60M | $108.10M |
| EPS (diluted) | $-3.40 | $1.40 | $3.03 | $6.15 | $5.73 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$193.33+76.44%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 27, 2026
- EPS actual vs est.
- $0.90 vs $1.19
- Surprise
- -24.37%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $0.0075
- Ex-dividend date
- Jan 9, 1992
ROG news
All ROG news- FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancerGlobeNewswire
- Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathyGlobeNewswire
- CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for systemic lupus erythematosus (SLE)GlobeNewswire
- 3 Key Reasons to Buy TTMI Stock Despite a 54% Six-Month SlideNasdaqTTMI, ROG, CPSH, NVT
- Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026GlobeNewswire
- Why Rogers Stock Popped 13% at the Open Before Cooling OffNasdaq
- Rogers: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesotheliomaGlobeNewswire
Rogers peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IOSPInnospec Inc. | 75.56 | -1.97% | $1.86B | vs ROG |
| NGVTIngevity Corporation | 53.75 | -3.95% | $1.82B | vs ROG |
| MTXMinerals Technologies Inc. | 57.97 | -1.58% | $1.80B | vs ROG |
| OLNOlin Corporation | 15.19 | -6.70% | $1.73B | vs ROG |
| CCChemours Company (The) | 10.88 | -7.80% | $1.64B | vs ROG |
| HUNHuntsman Corporation | 8.36 | -6.80% | $1.47B | vs ROG |
| KWRQuaker Houghton | 147.48 | -2.33% | $2.54B | vs ROG |
| STDNStandard Nuclear Inc. Class A | 8.14 | -9.66% | $1.28B | vs ROG |
Indexes, lists and sector
Rogers stock FAQ
What is Rogers's stock price today?
ROG last traded at $109.57 as of Nov 20, 4:00 PM EST, down 9.03% on the day. Prices are delayed at least 15 minutes.
Does Rogers pay a dividend?
Yes. Rogers pays $0.00 per share annually. The most recent dividend of $0.0075 had an ex-dividend date of Jan 9, 1992.
What is ROG's P/E ratio?
ROG trades at a trailing P/E ratio of 43.83 and a forward P/E of 23.30, compared with a median of 26.4 for its closest peers.
Who is Rogers's CEO?
Mr. Ali El-Haj is the chief executive officer of Rogers Corporation, which has about 3,000 employees.
Has ROG ever split its stock?
Yes. The most recent ROG stock split was a 2-for-1 split on May 30, 2000, one of 2 splits on record.
What is the ROG 52-week high?
The 52-week high for ROG is $169.00 and the 52-week low is $78.82. The stock is currently 35.2% below its high.